Uro-Mp

Quick links to important sections

Uro-Mp

Selected form

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Uro-Mp

Property Description
Active Ingredients Hyoscyamine Sulfate, Methenamine, Methylene Blue, Phenyl Salicylate, Sodium Phosphate, Monobasic, Anhydrous
Form Solid oral preparation (Capsule or Tablet)
Pharmacological Class Urinary Antiseptic Combination
Common Use Symptomatic relief of genitourinary discomfort
Origin Synthetic and Semisynthetic

What Type of Medication is Uro-Mp?

Uro-Mp is a prescription-only multicomponent oral formulation classified primarily as a Urinary Antiseptic Combination. This classification is clinically recognized due to the simultaneous, synergistic effects of its five active ingredients. This specific product is characterized by its combination of antispasmodic, antiseptic, and analgesic agents into a single solid oral preparation, typically a capsule or tablet. The presence of Hyoscyamine Sulfate gives the formulation a defining semisynthetic component, which is chemically related to naturally occurring anticholinergic alkaloids.

Composition: The Five Active Ingredients in Uro-Mp

The unique identity of Uro-Mp is established by its complex blend of Hyoscyamine Sulfate, Methenamine, Methylene Blue, Phenyl Salicylate, and Sodium Phosphate, Monobasic, Anhydrous. This blend is distinct from simple analgesics as it features a dual therapeutic approach. For example, the primary antiseptic action of Methenamine is critically dependent on the acidifying agent Sodium Phosphate, Monobasic, Anhydrous, which ensures its effective function within the urine. The remaining components provide crucial supportive roles: Hyoscyamine Sulfate for muscle relaxation and the other agents for symptomatic comfort.

General Purpose: Why is Uro-Mp Prescribed?

The overarching purpose of Uro-Mp is to offer combined symptomatic relief and localized antiseptic support for the urinary tract. This approach is beneficial in managing discomfort and muscle urgency, as the drug’s components work in concert to address both issues. The medication is specifically intended to manage the irritation, pain, and feeling of urgency associated with conditions affecting the bladder and urethra, facilitating a return to comfort and normalized function.

Regulatory References

  1. Uro-MP DailyMed Label
  2. Uro-MP DailyMed Monograph

What side effects are possible with Uro-Mp?

Possible Side Effects and Safety Information

The information presented reflects the adverse reactions and safety concerns documented in official government regulatory labeling for combination products containing the active ingredients in Uro-Mp. It is an interpretation of the high-level safety profile as classified by official authorities.

Documented Adverse Reactions by Physiological System

Adverse reactions are classified according to the organ system where they manifest, as listed in the official United States prescribing information.

System/Organ Class Officially Documented Effects
Central Nervous System / Nervous System Dizziness, Drowsiness, Blurred Vision (Ophthalmic).
Cardiovascular System Rapid Pulse (Tachycardia), Flushing.
Gastrointestinal System Dry Mouth (Xerostomia), Nausea, Vomiting, Fecal Discoloration.
Genitourinary System Difficult Micturition, Acute Urinary Retention, Urine Discoloration.

Special Safety Notes and Risk Tiers

Safety documents advise that certain signs may indicate a more serious reaction, including Rapid Pulse, Dizziness, or Blurring of Vision. The potential for Severe Hypersensitivity Reactions is also noted, though classified as rare. A common and expected characteristic of this medicine is the presence of blue or blue-green urine and sometimes stools, which is stated by regulatory labeling as harmless and ceasing upon discontinuation.

Population-Specific Safety Considerations

  • Older Adults (Geriatric): This group may have an increased risk of CNS effects, including excitement, agitation, drowsiness, or confusion.
  • Pediatric Patients: There is a specific caution regarding the risk of Reye Syndrome in children or adolescents with active varicella or influenza due to the salicylate component.
  • Pregnant and Nursing Individuals: Use is conditional on clear necessity, as components are known to cross the placenta and be excreted in breast milk.

Safety Constraints

Regulatory documentation specifies several serious conditions that may be incompatible with the medicine. These safety constraints include a documented history of Glaucoma, Gastrointestinal Tract Obstructive Disease, Myasthenia Gravis, specific forms of Cardiac Disease, and pre-existing risk of Acute Urinary Retention. A crucial interaction-related safety risk is the potential for Serotonin Syndrome, associated with the Methylene Blue component when administered with certain serotonergic psychiatric medications.

Overdose and Emergency Response

Uro-Mp Overdose and when to seek help

The official regulatory documentation defines the Uro-Mp overdose profile primarily through acute anticholinergic toxicity, which arises from its Hyoscyamine Sulfate component. Immediate medical attention is required in the event of accidental overdose or excessive intake; the regulatory information states that one must seek professional assistance or contact a Poison Control Center immediately.

Overdose presentation often involves symptoms such as blurred vision, dilated pupils, dry mouth, difficulty swallowing, rapid pulse (tachycardia), dizziness, and signs of central nervous system (CNS) stimulation. Severe toxicity is documented as potentially life-threatening, including the risk of respiratory muscle paralysis, psychosis, and progression to coma.

Management steps officially described in regulatory information include procedural measures like immediate lavage of the stomach and the institution of artificial respiration for severe cases. The label explicitly cites Physostigmine for intravenous use as an intervention. Specific overdose considerations note that infants and young children are especially susceptible to the toxic effects, while geriatric patients may exhibit heightened sensitivity.

Therapeutic Uses of Uro-Mp

What Uro-Mp Treats: Main Uses and Benefits

This medication is generally considered relevant for the management of symptoms associated with lower urinary tract irritation. This medicine is commonly used to help with the symptomatic relief of discomfort related to inflammatory or irritative states caused by infection, trauma, or medical procedures.

Uro-Mp is applied in addressing symptom clusters related to heightened physiological activity, such as burning, pain, urgency, and frequency. It is relevant when short-term symptomatic assistance is needed, often during phases when symptoms become more noticeable.

“It provides support that helps ease the overall symptom burden associated with acute or disruptive episodes.”

Supportive Management and Comfort

The medicine may be part of symptomatic management in situations involving certain distressing symptoms and conditions characterized by episodic or fluctuating manifestations. It assists with maintaining functional stability and may help patients cope more steadily during these periods of increased discomfort. Uro-Mp contributes to easing discomfort and supports general well-being by managing symptoms that interfere with routine activities.

Quick Fact: Focus on Symptomatic Relief in Acute Phases

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Uro-Mp is approved for use in adults experiencing symptoms of irritative voiding. The eligibility profile for this multicomponent medication is strictly defined by regulatory authorities based on age, existing medical conditions, and physiological status.

Contraindicated Populations (Must Not Use)

Use is contraindicated in patients with a known hypersensitivity to any component (Hyoscyamine, Methenamine, Methylene Blue, Phenyl Salicylate, or Sodium Phosphate). It must also not be used by patients with severe hepatic impairment or those diagnosed with glaucoma, myasthenia gravis, obstructive uropathy (like bladder neck obstruction), or obstructive gastrointestinal tract disease.

Age-Based and Conditional Restrictions

Population Group Regulatory Status
Children 6 years and younger Not Recommended (due to susceptibility to belladonna alkaloids).
Geriatric Patients Use with Caution (due to increased risk of agitation or confusion).
Severe Renal Impairment Use with Caution (due to reliance on renal elimination for a component).
Pregnancy FDA Category C (use only if clearly needed).
Nursing Mothers Caution should be exercised (components are excreted in breast milk).

Eligibility also requires caution in patients with certain cardiac diseases, including cardiac arrhythmias or congestive heart failure.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines interactions with Uro-Mp components as documented in official government regulatory sources, without providing clinical advice or therapeutic context.

Classification Interacting Agents or Products Constraint or Official Finding
Formally Contraindicated Serotonergic Agents (e.g., SSRIs, MAOIs, Triptans) Strictly Prohibited due to the risk of Serotonin Syndrome associated with the Methylene Blue component.
Interactions Affecting Efficacy Urinary Alkalizing Agents (e.g., Sodium Bicarbonate) Reduces the antiseptic effectiveness of Methenamine by interfering with the necessary acidic urinary environment.
Absorption & Timing Antacids and Adsorbent Antidiarrheals Reduced absorption of the Hyoscyamine component. Requires doses to be spaced at least 1 hour apart.
Pharmacodynamic Effects Other Anticholinergic Agents Co-administration may intensify the peripheral antimuscarinic effects of the Hyoscyamine component.
Food & Product Risk Alcohol Co-ingestion with the Phenyl Salicylate component is officially linked to an increased risk of gastrointestinal irritation and mucosal bleeding.
Population Caution Salicylates in Pediatric Patients Caution is advised regarding the Phenyl Salicylate component in children or teenagers with viral illnesses due to an increased risk of Reye's Syndrome.

The regulatory profile strictly mandates avoiding combination with Serotonergic Agents and specifies requirements for dose separation when co-administered with antacids or Ketoconazole. Furthermore, products that significantly increase urinary pH are documented to compromise the drug's intended antiseptic function.

Mechanism of Action

Uro-MP is a combination product that exerts its effect through multiple, distinct pharmacological domains to induce pathway modulation within the relevant physiological systems.


Urinary Tract Antiseptic Action

This domain involves methenamine, which hydrolyzes in an acidic urine environment to release formaldehyde. Formaldehyde is a nonspecific bactericidal agent that denatures proteins and nucleic acids, causing nonspecific bactericidal effect and modulating cascades involving mediator activity linked to microbial presence. This effect requires the maintenance of an acidic urine pH.


Parasympatholytic Smooth Muscle Modulation

The drug includes hyoscyamine sulfate, a parasympatholytic agent that targets muscarinic receptors on smooth muscles. By antagonizing muscarinic signaling, it limits overactive nerve-mediated contractions, modulating parasympathetic signaling to reduce smooth muscle contractility and resulting in reduced cholinergic-driven smooth muscle tone.


Local Signaling and Pathway Modulation

This cluster involves phenyl salicylate and methylene blue. Phenyl salicylate is metabolized to release salicylate, which yields a reduction in local nociceptive signal transmission. Methylene blue possesses weak, nonspecific molecular activity, further influencing local molecular activity within the genitourinary environment. Sodium phosphate monobasic also acts as an acidifier to optimize the methenamine cascade.

Dosage and Administration Information

Uro-Mp is administered as a solid oral preparation, supplied as a tablet or capsule, which establishes the official route of administration. The standard use pattern for adults requires the patient to take one tablet or capsule (a single unit dose) four times per day. This established regimen involves consistent administration intervals, typically scheduled to occur every six hours to maintain a steady use pattern.

The proper administration of this medicine requires specific conditions for optimal component delivery. Each oral dose must be followed by liberal fluid intake (such as water). Furthermore, to prevent potential interference, doses of Uro-Mp should be spaced at least one hour apart from any antacid or antidiarrheal medications. Patients are instructed to take the medicine for the full duration specified by their regimen; however, no studies exist to establish the safety of prolonged human use of this specific combination product.

For instances of missed timing, if a dose is almost due, the patient should skip the missed unit dose and continue with the next scheduled time. Doses must never be doubled to compensate for a missed interval. The use of this medicine is not recommended for pediatric patients aged six years and under, and older adults should exercise caution during use.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Uro-Mp


Evidence for Symptomatic Relief of Irritative Voiding

Research on Uro-Mp was studied for its use in periods of heightened symptom activity related to lower urinary tract irritation. Studies, including Randomized Controlled Trials (RCTs) and supporting regulatory data, have been applied in studies examining patient-reported experiences in Adults with conditions involving symptoms such as burning, pain, urgency, and frequency. These studies focused on patient-reported outcomes describing perceived discomfort.

Research highlights changes measured during the study period for these specific symptoms. The evidence provides insight into short-term changes that were observed over defined time intervals. Because this medicine was studied for acute discomfort, follow-up durations were limited to short-term periods, and long-term effects are not fully established by existing research.


Evidence for Managing Symptoms After Medical Procedures

Research explored the formulation's use for outcomes related to physical discomfort following certain medical procedures, such as catheterization or cystoscopy. Studies monitored outcomes such as pain and discomfort scores in the immediate, post-procedural period. Comparative evidence is lacking for the specific Uro-Mp combination when stacked against other post-procedure protocols.


Research on Local Antiseptic Support

The component methenamine, which is part of Uro-Mp, research examined its potential role in managing bacterial measurements in the urine. Evidence suggests that studies monitored bacterial measurements in the urine and the frequency of symptomatic urinary episodes in certain populations. The full, five-component Uro-Mp formulation has limited information regarding long-term measurements of the outcomes studied for antiseptic support.


Key Limitations and Areas of Uncertainty

The research base presents several limitations noted in scientific literature: Comparative evidence is lacking for the full product against contemporary therapies; sample sizes were modest in many studies; and follow-up durations were limited to acute use. Furthermore, the evidence quality varies across studies, often requiring extrapolation from the individual components, and data for certain groups (e.g., specific comorbidities, older adults) remain insufficient.

Key Studies & References

  1. Urimar-T (Methenamine, Sodium Biphosphate, Phenyl Salicylate, Methylene Blue, Hyoscyamine Sulfate) Extended Release Tablets [Regulatory Label]
  2. Urinary tract infection (lower): antimicrobial prescribing (NG109) - Symptomatic treatment context (NICE Guideline)

Frequently Asked Questions (FAQ)

Common questions about Uro-Mp (FAQ)


Q: Does Uro-Mp help with pain right away?

Official documents state that this medication is intended for the symptomatic relief of acute discomfort. However, regulatory labeling does not specify an exact time frame for when the onset of effects is observed, or when patients may notice the full benefits of pain relief.


Q: How quickly should I expect to notice Uro-Mp starting to work?

Studies and official information indicate that this medication was examined for its short-term changes in acute discomfort. However, the regulatory documents do not specify a precise time frame for when the onset of effects is typically observed.


Q: Can Uro-Mp be used by people who have other long-term health problems?

The official label lists specific existing medical issues—such as certain types of gastrointestinal tract disease, cardiac disease, and glaucoma—that may pose risks. For patients with these or other chronic conditions, regulatory guidance states it is necessary to evaluate the potential risks before use.


Q: Are there any foods or drinks that should be avoided when using Uro-Mp?

Official guidance identifies alcohol as needing to be avoided due to an increased risk of gastrointestinal irritation and mucosal bleeding. Additionally, the drug's antiseptic component requires an acidic urine environment. Therefore, consumption of foods, such as milk and most fruit juices, that may make the urine less acidic could potentially reduce the medication's intended effectiveness.


Q: Is Uro-Mp safe to take if I am already taking a lot of different vitamins?

Official guidance suggests disclosure of all medicines taken, including non-prescription products, vitamins, and any herbal or dietary supplements, before starting this medication. This is necessary for evaluation of potential interactions by a healthcare professional.


Q: What is the main difference between Uro-Mp and a typical antibiotic?

Uro-Mp is officially classified as a Urinary Antiseptic Combination, not a conventional antibiotic. Its antiseptic component works by releasing a nonspecific bactericidal agent and is typically not classified as a curative treatment for bacterial infections.


Q: If I miss taking Uro-Mp sometimes, will it still work?

The label provides instructions to skip a missed dose if it is almost time for the next one and resume the normal schedule. However, regulatory documentation does not detail how occasionally missing doses affects the intended effects of the treatment regimen.


Q: How long after stopping Uro-Mp does it stay in your system?

According to the Clinical Pharmacology section, one of the primary active components is absorbed and largely excreted in the urine, with most of it passing out of the body within 12 hours of administration.


Q: Does taking Uro-Mp affect my ability to drive or operate machinery?

The regulatory labeling notes that this medicine can cause certain adverse reactions affecting the central nervous system, including dizziness, drowsiness, and blurred vision. These reactions may impair a person's ability to drive or operate complex machinery. The label indicates that individuals should be aware of how the medicine affects them before engaging in activities requiring full attention.


Q: Can Uro-Mp be purchased without a prescription in some places?

Regulatory information specifies that this medication is classified as a prescription drug (Rx Only). This classification means a legal prescription from an authorized prescriber is required for dispensing.


Q: Why do doctors prescribe Uro-Mp for certain conditions?

It is prescribed according to its indicated uses, which are for the symptomatic relief of irritative voiding. This includes relieving local symptoms like pain, urinary frequency, and urgency that can accompany lower urinary tract irritation or diagnostic procedures.


Q: Do children ever use Uro-Mp, and is it suitable for them?

Official regulatory documents state that this medication is not recommended for children 6 years of age and younger. For older children, the dose, use, and suitability are required to be evaluated and individualized by a physician.


Q: Is Uro-Mp a narcotic or habit-forming drug?

This medication is not listed under the DEA Controlled Substances Act, as indicated in the product information. This means the drug is not classified as a narcotic or a federally controlled substance with potential for abuse.


Q: Can taking Uro-Mp change the results of certain lab tests?

Yes, the medication contains a dye component (Methylene Blue) that is known to change the color of urine and stool to blue or blue-green. This physical property may interfere with the accuracy or results of certain laboratory tests.


Q: Does Uro-Mp contain any dyes or common allergens?

Yes, the product contains coloring agents (dyes) as inactive ingredients. Furthermore, patients with a known history of sensitivity to belladonna alkaloids or salicylates are cautioned, as they may be intolerant of this medication.


Q: How long do most people continue to use Uro-Mp?

The medication is intended for acute use, as regulatory documents explicitly state that no studies have been performed to establish the safety of its prolonged use in humans.


Q: Is Uro-Mp used for conditions other than bladder discomfort?

The labeled indication for this medication is specifically restricted to the symptomatic relief of irritative voiding symptoms and discomfort related to the lower urinary tract.


Q: Is Uro-Mp studied for use in pregnant women?

The medication is classified as FDA Pregnancy Category C. The labeling clarifies that no studies have been conducted in either animals or humans. Official labeling states that the medication's use during pregnancy is conditional and requires a clear necessity.


Q: Are there special warnings about Uro-Mp for people with kidney problems?

Caution is recommended for use in patients with kidney problems, including severe renal impairment. This is because the elimination of one of the active components relies on proper kidney function.


Q: Does Uro-Mp require any special monitoring by a healthcare provider?

Official guidance states that a healthcare provider should monitor the patient's status during regular visits. This helps to evaluate the response to the medicine and if continued use is necessary.


Q: If Uro-Mp is taken daily, does its effectiveness decrease over time?

The drug is intended for short-term, acute use, and the regulatory documentation does not contain data on long-term daily administration. Therefore, the official information does not specifically address whether effectiveness decreases (tolerance develops) over time with daily use.


Q: What information is available about long-term use of Uro-Mp?

Regulatory documentation explicitly states that no studies have been performed to establish the safety of prolonged use in humans for this specific combination product. Available evidence is limited to short-term application.


Q: What are the most serious side effects that have been reported with Uro-Mp?

The regulatory label lists several severe adverse reactions, such as rapid pulse, severe dizziness, and acute urinary retention, that are associated with the drug. These are signs of serious effects that must be promptly communicated to a healthcare professional.


Q: What is known about the safety profile of Uro-Mp in clinical trials?

The official safety profile is defined by the known risks of the individual components and the adverse reactions listed on the label. Regulatory documents confirm that no studies exist to establish the safety of its prolonged use in humans.


Q: Does Uro-Mp affect the ability to use oral contraceptives?

Although oral contraceptives are not explicitly listed in interaction tables, the medication’s anticholinergic effects may decrease the absorption of other oral medications due to reduced gastrointestinal motility. Regulatory guidance suggests that a healthcare professional must evaluate all prescribed drugs to account for potential changes in absorption.


Q: Is it necessary to finish the entire course of Uro-Mp if I start feeling better?

Proper use guidelines generally advise that the medication is intended to be taken for the full duration of treatment as specified by a healthcare provider. This applies even if symptoms begin to improve before the course is finished.


Q: What is the likelihood of Uro-Mp interacting with common heart medications?

Regulatory labeling indicates that the drug is contraindicated or requires caution in patients with pre-existing heart conditions, such as cardiac arrhythmias or congestive heart failure. Therefore, it is necessary that all prescribed drugs are evaluated by a healthcare professional.


Q: Can Uro-Mp be taken at the same time as cold and flu medicine?

Caution is advised because cold and flu medicines may contain ingredients like sympathomimetics or anticholinergics. Co-administration could intensify the side effects of Uro-Mp or increase the risk of a serious reaction, such as Serotonin Syndrome.


Q: Does Uro-Mp have any known effects on sleep patterns?

Drowsiness is listed as a documented adverse reaction affecting the central nervous system. Because of this, the medication may indirectly affect a person's normal sleep patterns.


Q: How does the body generally process Uro-Mp?

The Clinical Pharmacology section details that the body processes the five components in different ways. For example, one component is absorbed, metabolized in the liver, and mostly excreted in the urine within 12 hours, while the Methylene Blue component is rapidly reduced to an active form before being excreted.


Q: What is meant by the 'pharmacology' of Uro-Mp?

Pharmacology, in this context, refers to the scientific description of how the drug works. It details the combined mechanism of action, such as how the Methenamine component provides antiseptic support and how the Hyoscyamine component causes smooth muscle relaxation.


Q: Can Uro-Mp be taken with or without food?

While the label requires liberal fluid intake, regulatory documentation notes that certain foods, such as milk and most fruit juices, can interfere with the acidic environment needed for the drug to work effectively. There is no specific instruction regarding food itself.

How should Uro-Mp be stored and disposed of?

How to Store and Dispose of Uro-MP Capsules

Official labeling defines specific storage requirements necessary to maintain product integrity and safety.

Storage Requirement Specification
Temperature Store at Controlled Room Temperature, between 15 C and 30 C (59 F and 86 F); keep from freezing or excessive heat.
Protection Protect from moisture and direct sunlight.
Container Rule Keep the dispensed container tightly closed; must have a child-resistant closure.

The medication must be kept out of the reach of children and pets during both storage and the disposal process. The product should be thrown away after the expiration date on the package, following instructions from a healthcare professional for safe disposal of unused or outdated medicine.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Uro-Mp found in:

A-Z Index: